Who
Kathleen Laporte
Director
Company insider
Files Form 4 as: Director, Q32 Bio; Director, Bolt Biotherapeutics; Director, Precipio; Director, CERo Therapeutics Holdings; Director, 89bio; Director, Affymax; Director, Transcept Pharmaceuticals; Director and 10% owner, Ista Pharmaceuticals.
In numbers
- Trades disclosed
- 162
- Buys
- 1
- Sells
- 15
- Bought
- $24K
- Sold
- $18.9M
- Companies
- 10
- Companies where not an officer
- 10
- First trade
- 20 Oct 2004
- Last trade
- 12 Jun 2026
- Last filed
- 21 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jun 2026filed 21 Jul 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,826 at $0.00 | filing |
| 12 Jun 2026filed 21 Jul 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,826 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —9,810 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —9,810 at $0.00 | filing |
| 10 Jun 2026filed 11 Jun 2026 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 10 Jun 2026filed 11 Jun 2026 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 15 Jan 2026filed 30 Jan 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | $64K23,272 at $2.75 | filing |
| 15 Jan 2026filed 30 Jan 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | $64K23,272 at $2.75 | filing |
| 15 Jan 2026filed 20 Jan 2026 | PRPO PrecipioLife-science tools | SEC FORM 4 Code A | $12K520 at $24.00 | filing |
| 15 Jan 2026filed 20 Jan 2026 | PRPO PrecipioLife-science tools | SEC FORM 4 Code A | $12K520 at $24.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | CERo Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —690,900 at $0.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | CERo Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —690,900 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PRPO Precipiooption or derivative · Life-science tools | SEC FORM 4 Code A | —1,500 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PRPO Precipiooption or derivative · Life-science tools | SEC FORM 4 Code A | —1,500 at $0.00 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,392 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,392 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,250 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,250 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,250 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,250 | filing |
News
No headline names them, or the companies they trade most, lately.